{
    "symbol": "KNSA",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-07 16:12:06",
    "content": " And as we said, around 60% of those Q2 early launch patients were still on therapy through the end of Q1, which again kind of builds into the confidence of duration potentially being around 12 months, although acknowledging it's a small cohort, the data will continue to evolve, and we need to see a more robust number of patients get into that time point and wait to see what the right-hand side of that curve looks like over time to be able to provide more information around the actual eventual duration."
}